Abstract
Acute myeloid leukemia (AML) is characterized by presence of 20% or more blasts at blood or bone marrow, interfering negatively in the production of the other blood cells with consequent anemia, neutropenia and thrombocytopenia. The AML treatment involves aggressive chemotherapy with survival bigger than five years. On the other hand, the survival is 40% lower than those subjected to the …